Online inquiry

IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4494MR)

This product GTTS-WQ4494MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD28 gene. The antibody can be applied in Lupus nephritis, Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001243077.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 940
UniProt ID P10747
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4494MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7838MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ6673MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ8467MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ8696MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ14925MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ10745MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ8212MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ9382MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW